NVX 408

Drug Profile

NVX 408

Alternative Names: NVX-408

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NuvOx Pharma
  • Class Fluorocarbons
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemorrhage; Haemorrhagic shock

Most Recent Events

  • 06 Jan 2017 Preclinical trials in Haemorrhage in USA (IV)
  • 06 Jan 2017 NuvOx Pharma and Jiangsu Nhwa Pharmaceutical agree to co-promote and co-develop NVX 408 in China for haemorrhagic shock and perioperative blood loss
  • 31 Aug 2014 Preclinical trials in Haemorrhagic shock in USA (IV) before August 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top